Amir T Fathi Selected Research

enasidenib

3/2024	Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
12/2023	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
11/2022	Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
11/2021	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
1/2021	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
4/2020	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
1/2019	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
1/2018	Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
10/2017	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amir T Fathi Research Topics

Disease

61	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2024 - 02/2009
30	Neoplasms (Cancer) 01/2023 - 01/2011
12	Leukemia 01/2023 - 03/2013
8	Hematologic Neoplasms (Hematological Malignancy) 04/2024 - 06/2014
8	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2024 - 03/2013
5	Thrombocytopenia (Thrombopenia) 04/2023 - 12/2017
4	Febrile Neutropenia 04/2023 - 10/2019
4	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 12/2022 - 01/2021
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 01/2016
4	Philadelphia Chromosome 01/2022 - 08/2016
3	Acute Promyelocytic Leukemia 05/2021 - 01/2018
3	Anemia 01/2020 - 01/2017
3	Glioma (Gliomas) 07/2017 - 06/2014
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2017 - 07/2013
2	Pathologic Complete Response 08/2022 - 11/2019
2	Infections 11/2020 - 06/2016
2	Blast Crisis (Blast Phase) 11/2020 - 11/2014
2	Hyperbilirubinemia 10/2017 - 08/2016
1	Multiple Myeloma 04/2024
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 04/2024
1	Primary Myelofibrosis (Myelosclerosis) 01/2024
1	Leukopenia 04/2023
1	Hypophosphatemia 01/2023
1	Exanthema (Rash) 01/2023
1	Carcinogenesis 01/2023
1	Pneumonia (Pneumonitis) 11/2021
1	Neutropenia 11/2021
1	Diarrhea 05/2021
1	Death (Near-Death Experience) 02/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 10/2020
1	Abnormal Karyotype 01/2019
1	Heart Failure 01/2018

Drug/Important Bio-Agent (IBA)

16	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2024 - 11/2012
9	enasidenibIBA 03/2024 - 10/2017
8	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 09/2009
7	alpha-hydroxyglutarateIBA 01/2019 - 11/2012
6	Tyrosine Kinase InhibitorsIBA 03/2024 - 07/2013
6	ivosidenibIBA 01/2024 - 01/2020
5	AnthracyclinesIBA 10/2020 - 09/2009
4	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 01/2021
4	venetoclaxIBA 08/2022 - 10/2020
4	fms-Like Tyrosine Kinase 3IBA 10/2020 - 12/2014
4	Lenalidomide (CC 5013)FDA Link 10/2018 - 09/2013
3	Immunoconjugates (Immunoconjugate)IBA 04/2024 - 01/2018
3	Phosphotransferases (Kinase)IBA 01/2023 - 01/2011
3	Biomarkers (Surrogate Marker)IBA 05/2022 - 02/2016
2	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2018
2	Monoclonal AntibodiesIBA 01/2022 - 01/2018
2	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2022 - 02/2021
2	EnzymesIBA 01/2021 - 01/2020
2	isocitric acid (isocitrate)IBA 04/2020 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2012
2	Asparaginase (Elspar)FDA Link 01/2018 - 08/2016
2	Glutamine (L-Glutamine)FDA Link 01/2018 - 04/2014
2	Imatinib Mesylate (Gleevec)FDA Link 08/2016 - 12/2011
2	Sorafenib (BAY 43-9006)FDA Link 03/2016 - 12/2014
2	Tyrosine (L-Tyrosine)FDA Link 01/2011 - 02/2009
1	FF-10101IBA 03/2024
1	TabletsIBA 01/2024
1	eprenetapoptIBA 04/2023
1	vorasidenibIBA 01/2023
1	ruxolitinibIBA 01/2023
1	proto-oncogene proteins pimIBA 01/2023
1	regorafenibIBA 05/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	Ad26COVS1IBA 01/2022
1	AntibodiesIBA 01/2022
1	Immunoglobulin A (IgA)IBA 01/2022
1	VaccinesIBA 01/2022
1	ArsenicIBA 05/2021
1	Immune Checkpoint InhibitorsIBA 12/2020
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2020
1	Fluconazole (Zonal)FDA LinkGeneric 11/2020
1	glasdegibIBA 10/2020
1	Alpha-Ketoglutarate-Dependent Dioxygenase FTOIBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	N-methyladenosineIBA 01/2020
1	Brentuximab VedotinIBA 01/2020
1	larotrectinibIBA 01/2020
1	gilteritinibIBA 10/2019
1	tagraxofuspIBA 01/2019
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 01/2019
1	Arginine (L-Arginine)FDA Link 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2018
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 01/2018
1	Etoposide (VP 16)FDA LinkGeneric 01/2018
1	ElectrolytesIBA 01/2018

Therapy/Procedure

53	Therapeutics 04/2024 - 01/2011
21	Drug Therapy (Chemotherapy) 01/2023 - 01/2008
4	Cell Transplantation 01/2023 - 01/2017
3	Induction Chemotherapy 02/2021 - 01/2017
3	Hematopoietic Stem Cell Transplantation 08/2016 - 06/2014
1	Palliative Care (Palliative Therapy) 12/2021
1	Blood Transfusion (Blood Transfusions) 01/2021
1	Stem Cell Transplantation 10/2020
1	Remission Induction 10/2020
1	Immunotherapy 01/2020
1	Duration of Therapy 10/2019